Preclinical research is at the core of effective drug development. Hera BioLabs is a contract research organization (CRO) utilizing revolutionary gene editing technologies to create improved preclinical models. Combining these transformative models with toxicology and efficacy studies to produce high-confidence, translational data; is what we call Precision Toxicology™ & Efficacy Screening.
Both the FDA and EPA, through their integral involvement in the TOX21 collaboration are invested in the modernization and transformation of toxicology and efficacy testing by encouraging less reliance on traditional animal models and the development of alternative models that are mechanism based, provide higher through-put and are of greater clinical relevance. To this end, Hera has successfully developed several fully severe combined immunodeficient (SCID) rat lines with applications in tumor cell line xenografts and patient derived xenograft (PDX) efficacy screening, allowing our clients to achieve accurate results. Furthermore, the humanization of the liver and immune system in Hera’s rat models is also underway, which is expected to revolutionize human specific liver toxicity screening, the availability of human hepatocytes, and the industry’s ability to test for human specific metabolites.